J&J Vaccine: Some CDC Advisors Question Warning’s Strength As Clot Reports Grow, Female Use Drops
Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.
You may also be interested in...
Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.
Moderna's mRNA-1273 vaccine prevented significant illness after two doses in all patients in the TeenCOVE trial, ages 12-18. The company will submit the data to global regulators in June. Meanwhile, J&J has applied for the Japanese approval of its vaccine, Moderna progresses plans in Korea, and India plans to ramp up vaccine supplies.
Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.